In this video, health care analyst David Williamson discusses the recent events around Orexigen Therapeutics, including today's rarely seen price-increasing dilutive offering. Is Orexigen a looming threat to obesity-drug-making heavyweights Arena and VIVUS? Watch and find out.
S&P 500
$5,916.93
+0.4%
+$24.35
DJI
$42,322.75
+0.6%
+$271.69
NASDAQ
$19,112.32
-0.2%
-$34.49
Bitcoin
$103,358.00
-0.2%
-$241.51
AAPL
$211.11
-0.6%
-$1.22
AMZN
$204.88
-2.6%
-$5.36
GOOG
$165.24
-0.9%
-$1.57
META
$643.49
-2.4%
-$15.87
MSFT
$452.47
-0.1%
-$0.47
NVDA
$134.64
-0.5%
-$0.70
TSLA
$342.64
-1.4%
-$5.04
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Orexigen is making moves.
David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Arena Pharmaceuticals
ARNA
VIVUS
VVUS
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Biohaven Stock Dove by Nearly 20% on Thursday
Why UnitedHealth Stock Is Imploding Today
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Is This Beaten-Down Stock a Buy Near Its 52-Week Low?
2 Catalysts Could Cause This 6%-Yielding Dividend Stock to Soar by the End of 2026
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.